The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

Using FAERS to Determine Medical Costs – a Payer Perspective

Posted by Brian Overstreet on March 31, 2017

We're happy to have a guest writer on the RxView blog this week, Alan Lukazewski, RPh – Director of Clinical Pharmacy at WEA Trust

WEA Trust is a not-for-profit health insurer serving Wisconsin public employers, their staffs and families.  In my role as Director of Clinical Pharmacy, I manage pharmacy benefits for WEA Trust, including prior authorization management, clinical program design, and specialty pharmacy management.  Within those areas, I focus attention on adverse drug event detection and prevention, especially in older adults. 

Last year, we partnered with Advera Health on a unique project to determine whether we could use data from the FDA Adverse Event Reporting System (FAERS) to determine total medical costs for a particular class of medicines.  Previously, Advera Health published a study detailing their methodology for calculating medical costs from FAERS data, but this would be the first study to pair FAERS data with specific claims data to determine downstream medical costs.

Read More

Topics: FAERS, RxCost, AMCP

How Memorial Hermann Uses an Evidence Aggregation Platform

Posted by Jim Davis on December 8, 2016

Healthcare systems are generally slow to adopt new technologies. For all the talk about leveraging “Big Data,” the industry has been even slower to adopt analytics to make those data actionable. In fact, not one state Medicaid agency currently uses an evidence aggregation platform with post-approval adverse drug events intelligence when creating preferred drug lists, writing prior authorization criteria, negotiating supplemental rebates, educating prescribers and dispensers, or performing prospective, concurrent, or retrospective drug utilization reviews. This is in spite of the fact that millions of patient lives are put at risk and billions of dollars are spent every year from adverse drug events. Yet there is no mandate to use readily available, reliable data to inform making decisions about prescription medicines.

Fortunately there are the outliers - innovators and early adopters that see things differently. They know that they can make a difference by incorporating new ideas and approaches to improve patient outcomes and their own bottom lines.

Read More

Topics: RxCost, Evidex, memorial hermann, real world data, hospitals, evidence aggregation platform, cost of drug adverse events, IDN, health system, clinical trial results, adverse events

How HEOR Can Demonstrate Cost Burden of Drug Adverse Events

Posted by Jim Davis on October 6, 2016

 


Health Economics and Outcomes Research (HEOR) teams are using evidence aggregation platforms to conduct observational and retrospective studies using both clinical trial results and real world data. Whether a single database is being used for analysis or a combination of multiple datasets are combined, the best evidence aggregation platforms will incorporate standardized analytics that allow for efficient and effective insight generation. One of the key resources a HEOR team needs is the ability to standardize the downstream medical costs of drug adverse events.

Read More

Topics: RxCost, Evidex, HEOR, real world data, evidence aggregation platform, cost of drug adverse events, clinical trial results, adverse events

Express Scripts’ 2017 Exclusions – Analysis Using Real World Data

Posted by Jim Davis on August 2, 2016


It has become tradition at Advera Health to look closely at the annual formulary exclusions that the large payers such as Express Scripts introduce every August. Using our safety scoring and costing algorithms we are able to quickly provide a top-line view into the effects of their decisions. 

Read More

Topics: Drug Safety, Drug Formulary, Express Scrips, RxCost

Safety Score & Cost Burden Analysis Update – Which Drugs have Riskiest Profiles?

Posted by Andrea Demakas on July 21, 2016

In June, the Advera analyst team combed through prescription and patient population data supplied by our partners at Evaluate Pharma to update our RxScore and RxCost analytics site-wide. The end result yielded 53 drugs with first-time RxScores and 69 drugs with first-time RxCosts.

Read More

Topics: RxScore, P&T, RxCost

JMCP Validates the Ability to Quantify the Safety Risk of Drugs

Posted by Bob Kyle on December 4, 2015

JMCP_Cover.pngFor the last few years, we have been working continuously to turn post-market patient data from the FDA’s Adverse Reporting system (FAERS) into insight that can be used by healthcare providers to quantify the costs and risks associated with the drugs that their patients are prescribed.  Along the way, we have had a number of “naysayers” tell us it cannot be done. 

Read More

Topics: RxScore, RxCost, JMCP

Subscribe to Email Updates